Tamoxifen and the uterus and endometrium

The Lancet · 1989 · vol. 333(8634) , pp. 375–376 · doi:10.1016/s0140-6736(89)91741-8 · PMID:18446929 · W2127828646
Other OA: closed CC0 ⤵ 34 in-corpus citations
Limited metadata. Only one source feed has indexed this record so far — no abstract, full text, or open-access copy is available through Endo Lab. The publisher's page (linked below) is the canonical location for the actual content. If you have institutional access, use "Find at my library".
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-12 ⓘ

This paper reviews the effects of tamoxifen on the uterus and endometrium, focusing on observed changes and potential clinical implications.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Antineoplastic Agents, Hormonal Breast Neoplasms Endometrial Neoplasms Tamoxifen Uterine Neoplasms Antineoplastic Agents, Hormonal Breast Neoplasms Breast Neoplasms Endometrial Neoplasms Female Humans Incidence Neoplasms, Second Primary Neoplasms, Second Primary Tamoxifen Uterine Neoplasms

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (17)

Cited by (31)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:05:19.467219+00:00
unpaywall
last seen: 2026-10-14T06:23:58.021457+00:00
License: CC0 · commercial use OK